Voyager Therapeutics Inc
Most Recent
Why Is Voyager Therapeutics Soaring Today?
Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX).
Analysts Remain Bullish on BioMarin Pharmaceutical
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.
Analyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.
Exploring Voyager Therapeutics’ Research Pipeline
Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications.